Gilead Sciences' Product Yescarta
Kite - a Gilead Sciences (GILD) Company, announced the U.S. FDA has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma (LBCL) refractory to first-line chemo-immunotherapy or that which relapses within 12 months of first-line chemo-immunotherapy.
Yescarta demonstrated a clinically meaningful and statistically significant . . .
This content is for paid subscribers.
Today’s Highlights April 4, 2022